Strona 74 - Leczenie w Stambule (Turcja)

Dr. Murat Toygar Guler is a surgeon in orthopedics and otolaryngology (ENT). He graduated from Istanbul University Cerrahpaşa Faculty of Medicine. He completed his residency in Orthopedics and Traumatology at Bolu Abant Izzet Baysal University. He provides surgical and non-surgical care for musculoskeletal disorders.

Expertise: trauma surgery; knee, hip, and shoulder disorders; spinal deformities and herniated discs; sports injuries; pediatric orthopedics.

Experience: Bolu Abant Izzet Baysal University Orthopedics and Traumatology Clinic; Zonguldak Caycuma and Bolu Izzet Baysal State Hospitals; Private Atlas, Lokman Hekim, Medipol University Pendik, and Aksu Goztepe Hospitals. Known for precision and a patient-focused approach.

Obszary zainteresowań

• Dziecięca chirurgia rekonstrukcyjna układu moczowo-płciowego
• Hipospadia
• Obrzezanie
• Chirurgia onkologiczna
• Wrodzone nieprawidłowości górnego i dolnego układu moczowego
• Chirurgia noworodków
• Dziecięca chirurgia brzuszna

Edukacja
 

• 1997 - Uniwersytet 19 Mayıs
• 1998 - Krajowy Kongres Chirurgii Dziecięcej, Najlepsze badanie naukowe
• 2001 - Uniwersytet Kocaeli
• 2007 - Rząd Kosowa
• 2009 - Uniwersytet Yeditepe
• 2009 - Kongres Arabii Saudyjskiej, Najlepsze badanie kliniczne

Doświadczenie
 

• Liceum FMV Işık
• Wydział Medyczny Uniwersytetu Stambulskiego Cerrahpaşa
• Uniwersytet Ondokuz Mayıs
• Szpital Dziecięcy Zeynep Kamil
• Wydział Medyczny Uniwersytetu Kocaeli
• UT Southwestern Medical Center, pediatryczna urologia, Dallas, USA
• Centrum Medyczne Uniwersytetu Ege, pediatryczna urologia
• Uniwersytet Yeditepe

Prof. dr Selami Sozubir jest autorem 65 publikacji naukowych, które uzyskały ponad 11 000 odczytów i niemal 1 000 cytowań, co odzwierciedla jego istotny wkład w rozwój chirurgii dziecięcej i urologii.

Dr. Haluk Inal is a urologic surgeon. He graduated from the GATA Faculty of Medicine. He completed his specialty training in urology at Haydarpaşa GATA Training and Research Hospital. He has decades of clinical and surgical experience. He provides advanced, minimally invasive urologic care.

Expertise: endourology (kidney stones, ureteral obstruction, urinary tract problems); prostate disease (BPH, prostate cancer); urologic oncology (kidney, bladder, testicular cancers); andrology and male health (erectile dysfunction, infertility); pediatric urology (undescended testis, hypospadias, congenital anomalies). He is known for precise, safe, and patient-focused care.

Dr. Ahmed Fatih Oguc is a specialist in gynecology and obstetrics. He is known for his skill and dedication to women’s health. He graduated from Trakya University Faculty of Medicine. He completed his specialization at Hacettepe University Faculty of Medicine.

Dr. Oguc has worked at leading healthcare institutions. He is committed to high standards of patient care and has earned strong patient satisfaction. He is a member of the Eskisehir Medical Chamber. This shows his commitment to professional growth and medical excellence.

Areas of Interests

• All skin, hair and nail diseases
• Aesthetic and cosmetic dermatological applications
• Dogol botox (wrinkle treatment, player botox)
• Sweating Botox
• Filling applications
• Stem cell therapies, exosome therapy
• Mesotherapy (hair and face mesotherapy, Paris glow)
• PRP
• Spot treatments
• Laser treatment applications
• Non-surgical skin rejuvenation
• Youth vaccinations
• Acne and acne scar treatment
• Eczema, seborrhoeic dermatitis, urticaria, allergic skin diseases, rosacea, psoriasis
• HPV, sexually transmitted diseases
• Cryotherapy, electrocauterisation, applications
• Nevus (mole) examination, follow-up and surgical mole removal
• Dermatological surgical procedures

Education:

• Mersin Hacı Sabancı Anatolian High School
• Mersin University Faculty of Medicine
• Çukurova University Department of Dermatological and Venereal Diseases

Experience:

• Liv Hospital Ulus

Dziedzina medycyny, której zainteresowania i działania są szczególne

Skanowanie molekularne

Onkologia nuklearna

Leczenie radionuklidami

Wykształcenie i doświadczenie

2018- Prywatny Szpital LIV Ulus

2015-2018 Uniwersytet w Stambule Bilim, Szpital Şişli Florence Nightingale

2006-2015 Mersin University Master of Science w dziedzinie medycyny nuklearnej

2005-2006 Centrum Medyczne Ankara Özel Denge

2004 Wydział Lekarski Uniwersytetu Hacettepe

Szkolenie specjalizacyjne: 2000-2004 Uniwersytet Hacettepe, tytuł magistra nauk w zakresie medycyny nuklearnej

Studia licencjackie: 1993-1999 Wydział Lekarski Uniwersytetu Hacettepe

Członkostwa

Czasopismo bólu mięśniowo-szkieletowego

Turecki Dziennik Nauk Klinicznych

Obrazowanie molekularne i terapia radionuklidowa

Dziennik raportów przypadków klinik tureckich

Czasopismo Badań Klinicznych i Eksperymentalnych

Czasopismo Medycyny Klinicznej i Analitycznej

Czasopismo nauk o zdrowiu Uniwersytetu Acıbadem

Stowarzyszenie Medycyny Nuklearnej w Turcji

Studiował na Wydziale Lekarskim Uniwersytetu w Ankarze.

Ukończył studia medyczne w 2010 roku. W latach 2010-2011 pracował jako lekarz rodzinny w dystrykcie Özalp w Van ze względu na obowiązek służby wojskowej.

W latach 2011–2016 doktor Mehmet ukończył specjalizację z kardiologii na Wydziale Kardiologii Uniwersytetu Cumhuriyet.

W latach 2016–2018 pracował jako lekarz specjalista w dzielnicy Erciş w mieście Van w ramach obowiązku służby wojskowej. Dr Maraseli pracuje jako lekarz specjalista w Szpitalu Międzynarodowym Avicenna od sierpnia 2018 r.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Areas of Interests

• Demyelinating Diseases and MS
• Peripheral Neuropathy and Motor Neuron Disease (ALS)
• Neuromuscular Junction Diseases (MG)

Education 

• M.Sc. Faculty of Medicine, Ondokuz Mayıs University  1990
• Specialization in Medicine  Neurology,  Ankara Training and Research Hospital 1997
• Minor Specialization  Clinical Neurophysiology, Medical Specialization Board 2011

Experience

• Doctor MoH Kastamonu and Samsun Health Center No. 7 1990-1992
• Dr. Res.Assist. Ankara Training and Research Hospital Neurology Clinic 1992-1997
• Assoc. Dr. Abant İzzet Baysal University Düzce Faculty of Medicine 1999-2006
• Assoc.Dr. Duzce University Faculty of Medicine 2007-2011
• Prof.Dr  Duzce University Faculty of Medicine  2011-

Dr. Ugur Boylu is a Professor of Urology. He is known for his skills in Robotic Surgery, Urological Oncology, and Endourology. He treats urological cancers and performs minimally invasive procedures. Dr. Boylu has played a key role in improving techniques in his field.

He has written 72 scientific papers and presented 193 congress abstracts. He has also contributed to 20 books. His work has received over 1,150 citations, and his h-index is 19. Dr. Boylu is accredited by the Turkish Urology Association and the European Association of Urology.

Areas of Interests

• General Urology
• Andrology
• Functional Urology

Education

• Selim Sırrı Tarcan Primary School
• Sisli Terakki High School
• 19 Mayıs University Faculty of Medicine / Urology

Experience

• Liv Hospital Vadistanbul
• Memorial Şişli Hospital Urology
• Şebinkarahisar State Hospital Chief Physician

Research

• Oxidative with Resistive Index in Varicocele
• Relationship Between Stress Factors

Publications

• Effectiveness of Flexible Uteronoscopy and Laser Lithotripsy for Multiple Unilateral
• Ontrarenal Stones Smaller Than 2 cm

Edukacja

Uniwersytet Osmangazi, licencjat z medycyny 1995 – 2003

Uniwersytet Celal Bayar, specjalność: chirurgia plastyczna, rekonstrukcyjna i

Klinika Chirurgii Estetycznej 2009 – 2015

Doświadczenie

Kartal Dr. Lütfi Kırdar Szpital Kształcenia i Badań, Klinika Chirurgii Plastycznej, Rekonstrukcyjnej i Estetycznej 2015 – 2021

Uniwersytet Bahçeşehir Wydział Lekarski Park Medyczny Szpital Göztepe Klinika Chirurgii Plastycznej, Rekonstrukcyjnej i Estetycznej 2021 – 2021

Kartal Lütfi Kırdar State Hospital, Klinika chirurgii plastycznej, rekonstrukcyjnej i estetycznej 2019 – 2021

Szpital Lokman Hekim w Stambule – chirurgia plastyczna, rekonstrukcyjna i

Klinika Chirurgii Estetycznej 2022 - Dzisiaj

Pulmonolog dziecięcy

Dziedziny medycyny, które mnie interesują

Ostre i przewlekłe problemy z oddychaniem

Zakażenia układu oddechowego.

Procedury diagnostyczne i lecznicze bronchoskopii

Astma

Problemy z oddychaniem podczas snu

Mukowiscydoza

Gruźlica

Edukacja

Uniwersytet w Stambule Wydział Lekarski w Stambule (1991-1997)

Szpital Kształcący i Badawczy Göztepe, Oddział Pediatrii, 1997-2002

Wydział Lekarski Uniwersytetu Marmara, Katedra Chorób Klatki Piersiowej Dziecięcej, 2004-2007

Wzruszenie religijne

Klinika Pediatrii Szpitala Kształcenia i Badań w Göztepe, Specjalista Pediatrii, 2002-2004

Szpital Kształcenia i Badań Chorób Klatki Piersiowej Sureyyapasa, Specjalista Chorób Klatki Piersiowej Dziecięcej, 2007-2010

Wydział Lekarski Uniwersytetu Bezmialem Vakıf, Katedra Pediatrii, Katedra Chorób Klatki Piersiowej Dziecięcej, Specjalista Chorób Klatki Piersiowej Dziecięcej, Wykładowca, 2010-2023

Szpital Liv, 2023-

Dr. Caner Yegin is an experienced endodontist. He focuses on advanced root canal treatments and dental trauma care. He graduated from Yeditepe University Faculty of Dentistry in 2010. He completed his PhD in Endodontics at Yüzüncü Yıl University in 2015.

Dr. Yegin has published many scientific articles. He has performed more than 2,000 endodontic procedures. He is known for handling complex cases and providing patient-focused care. Dr. Yegin is accredited by top dental associations. He also attends international conferences regularly.